Neos Therapeutics, Inc. (NEOS) Financial Analysis and Rating
Comparison Analysis Based on SEC Data
Company Name | Neos Therapeutics, Inc. |
Industry (SIC) | 2834 - Pharmaceutical Preparations |
Revenue in 2019 | $64,649 thousand (ranked #218 out of 533 companies in the industry) |
Assets as of 12/31/2019 | $90,873 thousand (ranked #351) |
Analyzed report | 9/30/2019 (filed 11/08/2019) |
Year:
Financial Position and Performance Annual | Quarterly
Compared with Q3 2019 industry ratios | Change during the quarter |
---|---|
worse |
unchanged |
Compared with all listed companies |
---|
worse |
Financial Ratios Benchmarking
Finanancial Ratio | Comparison of 9/30/2019 company ratios | ||
---|---|---|---|
with Q3 2019 industry ratios (28 - Chemicals And Allied Products) |
with all listed companies | ||
Solvency Ratios | |||
Debt ratio |
1.03
0.43
|
1.03
0.63
|
|
Debt-to-equity ratio |
Negative equity
|
Negative equity
|
|
Interest coverage ratio |
-0.10
-7.31
|
-0.10
1.86
|
|
Liquidity Ratios | |||
Current Ratio |
1.11
3.48
|
1.11
1.54
|
|
Quick Ratio |
0.89
2.03
|
0.89
0.99
|
|
Cash Ratio |
0.41
2.37
|
0.41
0.41
|
|
Profitability Ratios | |||
Profit margin |
-11.7%
-83.1%
|
-11.7%
3.3%
|
|
ROE (Return on equity), after tax |
Negative equity
|
Negative equity
|
|
ROA (Return on assets) |
-9%
-40.4%
|
-9%
0.6%
|
|
Activity Ratios | |||
Asset turnover (days) |
475
1142
|
475
749
|
|
Receivables turnover (days) |
129
60
|
129
51
|
|
Resulting score | -0,4 | -0,9 |
Year:
Additional Ratios (not used in score calculation)
Finanancial Ratio | Comparison of 9/30/2019 company ratios | ||
---|---|---|---|
with Q3 2019 industry ratios (28 - Chemicals And Allied Products) |
with all listed companies | ||
Profitability Ratios | |||
Gross margin |
63.2%
49.6%
|
63.2%
41%
|
|
Operating margin (Return on sales) |
-1%
-25.5%
|
-1%
7.6%
|
|
Activity Ratios | |||
Inventory turnover (days) |
172
119
|
172
76
|
|
EBIT | $(0)M | ||
EBITDA | $-48000 |
Auditor's Conclusion
We have performed a comparative analysis of the balance sheet and income statement of Neos Therapeutics, Inc. (hereafter – the "Company") for Q3 2019 as submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In the analysis, we have compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the specific industry sector and for all companies. The averages are calculated using data from Q3 2019 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have drawn a general conclusion about the quality of the company's financial condition. Calculations and summary conclusions are performed in a computerized manner using software and methodologies developed by ReadyRatios.
As a result of the analysis of the key financial ratios of the Company, we have established the following. The financial condition of Neos Therapeutics, Inc. in 2019 is worse than the financial condition of half of all companies engaged in the activity "Pharmaceutical Preparations".
A comparison of the Company's financial ratios with average ratios for all business activities leads to the same conclusion. The financial position of Neos Therapeutics, Inc. is worse than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.
Financial Position and Performance History
More on Neos Therapeutics, Inc.
Closest Competitors
Company | USD ($), in Millions | |
---|---|---|
Revenue | Assets | |
VIVUS, Inc. | 70 | 218 |
Blueprint Medicines Corporation | 67 | 708 |
Avid Bioservices Inc. | 64 | 105 |
MacroGenics Inc. | 64 | 313 |
Financial Data Source and Analysis Principles
The above is a comparative analysis of the company's financial position and performance. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is made using the eleven key financial ratios (see the table above). The company's financial ratios are compared with the median of the ratios for all companies and for companies in the same industry, as well as to the quartiles of these ratios. Each ratio value is assigned a score between -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis, the individual scores are weighted equally to produce an overall score ranging from -2 and +2.
much better (+1 - +2incl) | |
better (from 0.11 to +1incl) | |
about the same (from -0.11incl to +0.11incl) | |
worse (from -1incl to -0.11) | |
much worse (from -2incl to -1) |
Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:
significantly improved (positive change of more than 1 point) | |
improved (positive change of less than 1 point) | |
unchanged (little or no change in score, no more than 0.11 points) | |
deteriorated (the score has decreased by less than 1 point during the year) | |
deteriorated significantly (the score has decreased by more than 1 point during the year) |
Please note that this analysis does not indicate that the company's financial position is good or bad, but rather describes it in comparison to other U.S. businesses. For a detailed financial analysis, please use "ReadyRatios Financial Analysis" - load the data into the program>>